Antimalarial Drug II

1. Front Matter

   Pages I-XVIII

   PDF

2. Antimalarial Drugs in Current Use

   1. Front Matter

      Pages 1-1

      PDF

   2. 4-Aminoquinolines

      • E. W. McChesney, C. D. Fitch

      Pages 3-60

   3. Quinine and Quinine Analogues

      • W. Hofheinz, B. Merkli

      Pages 61-81

   4. 8-Aminoquinolines

      • P. E. Carson

      Pages 83-121

   5. Sulphonamides and Sulphones

      • H. J. Scholer, R. Leimer, R. Richle

      Pages 123-206

   6. Dihydrofolate Reductase Inhibitors

      • R. Ferone

      Pages 207-221

3. Novel Methods of Drug Development

   1. Front Matter

      Pages 223-223

      PDF

   2. Drug Combinations

      • W. Peters

      Pages 225-236

   3. Repository Preparations

      • D. F. Worth, L. M. Werbel

      Pages 237-252

   4. Cell Targeting of Primaquine

      • A. Trouet, P. Pirson, R. Baurain, M. Masquelier

      Pages 253-264

4. Recent Developments in Antimalarials

   1. Front Matter

      Pages 265-265

      PDF

   2. Drugs with Quinine-like Action

      • T. R. Sweeney

      Pages 267-324

   3. 8-Aminoquinolines

      • T. R. Sweeney

      Pages 325-342

   4. Lapinone, Menoctone, Hydroxyquinolinequinones and Similar Structures

      • A. T. Hudson

      Pages 343-361

   5. 4-Aminoquinolines and Mannich Bases

      • T. R. Sweeney, R. O. Pick

      Pages 363-385

   6. Triazines, Quinazolines and Related Dihydrofolate Reductase Inhibitors

      • P. Mamalis, L. M. Werbel

      Pages 387-442

   7. Antibiotics

      • K. H. Rieckmann

      Pages 443-470

   8. Miscellaneous Compounds

      • D. Warburton

      Pages 471-495

5. Prevention of Drug Resistance

   1. Front Matter

      Pages 497-497

      PDF

The construction of this volume has been guided by two personal convictions. Experience in the field of experimental chemotherapy, both in the pharmaceutical industry and academia, has convinced us that recent quantum technological advances in biochemistry, molecular biology, and immunology will permit and, indeed, necessitate an increasingly greater use of rational drug development in the future than has been the custom up to now. In Part l, therefore, we asked our contributors to provide detailed reviews covering the biology of the malaria parasites and their relation with their hosts, the experimental procedures including culture techniques that are necessary to take a drug from primary screening to clinical trial, and an account of antimalarial drug resistance. Our second conviction is that many research workers are all too loath to learn from the lessons of the past. For this reason we asked the contributors to Part 2 of this volume to review very thoroughly the widely scattered but voluminous literature on those few chemical groups that have provided the antimalarial drugs in clinical use at the present time. Much can be learned from the history of their development and the problems that have arisen with them in man. Some indeed may still have much to offer if they can be deployed in better ways than they are at present. This question has been taken up by several authors.

• Drugs
• biochemistry
• biology
• chemistry
• chemotherapy
• clinical trial
• drug
• drug development
• drug resistance
• immunology
• malaria
• molecular biology
• parasite
• research
• resistance

• London School of Hygiene and Tropical Medicine, London, Great Britain

  Wallace Peters

• Wellcome Research Laboratories, Berkhamsted, Herts., Great Britain

  William H. G. Richards

Policies and ethics